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H 
'ematopoiesis,  the  production  of blood  cells,  is a  dy- 
~namic process, the regulation  of which under normal 
conditions  must be a  tightly controlled  process  (1-7).  Ab- 
normalities  in this process no doubt lead to acceleration  of 
malignant  and  non-malignant disorders.  It is  over the  last 
40 yr that these normal and abnormal processes have begun 
to  be  unravelled  and  better  defined.  This  is  in  large  part 
due  to the  development of in vitro  and in vivo assays that 
recognize and allow quantitation  of different subsets of he- 
matopoietic  stem  and  progenitor  cells.  Stem  cells  are  de- 
fined as cells with multipotential lineage differentiation  ca- 
pacity  and  the  ability  to  self-renew  (make  more  cells  of 
their  own  kind).  The  earliest  stem  cells  would  be  those 
with  the  greatest  self-renewal  capacity and would  include 
the  long-term  marrow  repopulating  cell.  Stem  cells  with 
less self-renewal and differentiation  capacity exist and were 
originally defined by the in vivo spleen colony forming cell 
assay in mice.  Progenitor  cells  are  considered  to  have less 
self-renewal capacity, but the earliest subsets of these can be 
multipotential. 
We now know that hematopoiesis is regulated by an in- 
teracting network of cell-cell and cytokine-cell interactions 
(1-7).  Hematopoietic  stem and  progenitor  cells  are  influ- 
enced in their capacity to proliferate, differentiate, and pos- 
sibly to self-renew, by accessory cell-derived biomolecules, 
most  of which  can  be  classified  as  cytokines.  It is  only in 
the last 15 or so years that our knowledge of cytokines and 
their actions has blossomed. This is due to the recombinant 
DNA  technology revolution  that has allowed  the identifi- 
cation,  cloning and expression  of an increasing number of 
genes for cytokines  and  their  receptors.  We  are  at a  stage 
where  the  in  vitro  actions  of cytokines  which  were  first 
noted in the laboratory are rapidly translated into preclini- 
cal and clinical  studies  to  assess  the  efficacy of these  cyto- 
kines for potential  clinical benefit  (8-12).  The most obvi- 
ous of these translational efforts have been with the colony 
stimulating factors such as erythropoietin,  granulocyte  col- 
ony  stimulating  factor,  granulocyte-macrophage  colony 
stimulating factor, and most recently, thrombopoietin. 
There  are  now  over  50  bioactive  molecules  that  are 
known  to  influence  stem  or  progenitor  cell  proliferation 
and differentiation by stimulating, suppressing or enhancing 
the stimulation or suppression of these cells (1-7,  13). These 
effects can be direct on the  stem or progenitor cells them- 
selves, actions which are most rigorously determined in vitro 
with an initial  culture  of a single isolated stem or progeni- 
tor cell  (14-16),  or the  effects can be indirectly  mediated. 
This latter effect involves accessory cells which  can be in- 
duced by a number of stimuli, including  cytokines, to pro- 
duce and release a single, but more likely a group of cyto- 
kines  (1-7,  17-23)  which  can then directly act on stem or 
progenitor  cells or have a  cascading effect on induction  of 
the  production  or release  of additional  cytokines  or other 
biologically active molecules. 
Accessory cells can be mature morphologically recogniz- 
able blood  cells,  such  as  lymphocytes  (both  T  and  B  cells 
have  been  implicated  although  most  is  known  about  T 
cells),  monocytes,  macrophages  and  natural  killer  cells,  or 
stromal  cell  elements  such  as  fibroblasts,  endothelial  cells, 
epithelial cells, adipocytes and muscle cells (1-7,  17-23). 
A listing of biologically active molecules with known di- 
rect or indirect effects on stern and progenitor cell prolifer- 
ation and differentiation is shown in Table 1 (1-7,  24-30). 
This listing is not meat to be all-inclusive as new cytokines 
are still being discovered.  It is in this context that the article 
by Fossiez et al.  (31)  in this issue of the Journal  of Experi- 
mental  Medicine,  which  describes  the  cloning  and  action 
of expressed human IL-17, is of interest.  This study follows 
up  on the  cloning of murine  IL-17  (cytotoxic  T-lympho- 
cyte-associated antigen-8,  CTLA-8)  (32)  and complements 
the  recent  studies  of Yao  and  colleagues regarding  human 
lL-17 (33) and its novel receptor (34). 
Murine  IL-17 was identified as part of a search to detect 
novel molecules involved in functions  of the immune sys- 
tem (32). This gene was found as a single copy in cells from 
mice,  rats and  humans  and was mapped  at a  single site on 
mouse chromosome 1A and human chromosome 2q31. Mu- 
rine IL-17 cDNA contained an opening reading frame that 
encoded a putative protein of 150 amino acids, which turned 
out to be 57% homologous to the putative protein encoded 
by the open reading frame (OILF) 13 gene ofa T-lympho- 
tropic virus, herpesvirus Saimiri. This suggested another vi- 
rus-captured  gene  with  possible  functional  activity.  A 
number  of such  virus-captured  genes,  hypothesized  to  be 
important  for the  residency  of viruses  in  mammalian  sys- 
tems,  have  been  previously  reported  (reviewed  in  refer- 
ences 31-34),  including  that of IL-10, which  has 70% ho- 
mology with  an EBV gene,  BCRF1  (35).  In the paper by 
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ORF13, had some activities similar to that of human IL-17, 
much like BCRF1  and IL-10 that were shown to have some 
activities in common (35). 
Of particular  interest  is  the  rather  restricted  set  of cells 
that produce  IL-17  (31-34).  This contrasts with the  ubiq- 
uitous  nature  of cells  expressing  the  IL-17  receptor  gene 
(34)  although whether all cells expressing the IL-17 recep- 
tor  will  respond  to  IL-17  is  not  yet  known.  Moreover, 
whether the ubiquitous  expression of the murine IL-17 re- 
ceptor  gene  will  also  be  seen  in  the  human  system  will 
need  to  be  evaluated.  Of the  large  number  of cell  types 
evaluated for expression  of IL-17, it is the  T-lymphocytes 
that appear to be  the  major source  of IL-17  (31,  33);  the 
IL-17 gene  under  normal conditions  needs  to be induced 
for production  of IL-17.  In  particular,  it  is  the  activated 
memory CD4 + T  cell subset that has been implicated as an 
IL-17 producer (31). Whether different stimuli will be able 
to  activate  IL-17  production  in  other  cells,  and  whether 
IL-17  itself has  a  role  in  IL-17  production  remains  to  be 
determined.  A  number of cytokines,  at first thought  to be 
very restricted  in production  were  later found  to be more 
broadly produced.  The exact intracellular molecular mech- 
anisms oflL-17 production have also to be worked out. How 
much effort is made in this direction may reflect how rele- 
vant IL-17 is found to be in the regulation  of the immune 
and hematopoietic  systems,  and whether  or not  IL-17 can 
be used in a clinical sense for treatment of certain disorders. 
Upon  the  discovery  of any new  biologically  active  cy- 
tokine,  high  hopes  are  usually  engendered  that  the  cyto- 
kine will be of importance to a functional  system and that 
the cytokine, or perhaps a soluble form of the cytokine re- 
ceptor,  may be clinically useful.  Whether  this  turns  out to 
be the case or not will require  time and effort. That IL-17 
has  some interesting  characteristics  is  clear.  Human  IL-17 
and its virus "trapped" counterpart ORF13  have the capac- 
ity to induce  the production  of other cytokines from stro- 
mal cell  elements,  such  as  fibroblasts,  endothelial  cells and 
epithelial cells (31,  33).  Thus,  it has been determined  that 
IL-17  can  induce  the  release  of IL-6,  IL-8,  G-CSF,  and 
PGE 2,  and  can also  enhance  the  surface expression  of the 
intracellular  adhesion  molecule-1  (ICAM-1)  (31,  33).  In- 
terestingly  these  induced  molecules  have  different  activi- 
ties.  IL-6 has been implicated in a number of activities in- 
cluding growth of hematopoietic stem and progenitor cells 
and their expansion  ex vivo (36-38).  IL-8 has been shown 
to have myelosuppressive activity in  vitro and  in vivo for 
stem and  immature  subsets  of myeloid progenitors  (7,  26, 
39, 40). G-CSF has early and later acting effects on stimula- 
tion  and  acceleration  of hematopoiesis,  especially  of the 
neutrophil lineage (1-7). Prostaglandin E  has demonstrated 
enhancing activity for erythropoiesis and suppressing activ- 
ity  for  lymphopoiesis  and  myelopoiesis,  most  specifically 
for monocytopoiesis (1-7). Thus,  through the induction  of 
production of a number of cytokines, a single cytokine can 
have a broad set of not entirely predictable  effects that can 
be seen as a summation of all events,  some of which  have 
the potential of counterbalancing each other. 
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I can remember a time in the 1970s when scientists con- 
sidered a molecule to be relevant physiologically only when 
a  very  specific  function  could  be  demonstrated  for  that 
molecule. It was considered that a molecule with many end 
functions  could not be of significance  to cell regulation.  It 
is  abundantly  clear  now  that  all  cytokines  are  relatively 
pleiotropic in action. So where does this place IL-17 in the 
overall setting of those cytokines listed in Table 1? Many of 
those biomolecules listed have, as at least one of their func- 
tional  capacities,  the  ability to induce  the  release  of other 
cytokines from accessory cells, be these stromal or hemato- 
Table 1.  Biomolecules with Known Direct or Indirect Actions on 
Hematopoietic  Stern and Progenitor Cells 
Interleukins (IL) 
IL-1 to IL-17 
Colony Stimulating Factors (CSF) 
Granulocyte (G)-Macrophage (M)-CSF 
G-CSF 
M-CSF 
Eosinophil (Eos)-CSF (=IL-5) 
Multi-CSF (=IL-3) 
Erythropoietin (Epo) 
Thrombopoietin (TPO) 
Tumor Necrosis Factor (TNF)-~x, -13 
Interferons (IFN)-ot, 13, ~/ 
Transforming Growth Factor (TGF)-13 
Activin 
Inhibin 
H-Ferritin 
Lactoferrin 
Prostaglandin (PG)E 1, E 2 
Vascular Endothelial Cell Growth Factor (VEGF) 
Macrophage Stimulating Protein (MSP) 
Chemokines 
Macrophage Inflammatory Protein (MIP)-lot 
MIP-113 
MIP-2ot (=GRO-13) 
MIP-213 (= GRO-~/) 
GRO-c~ 
IL-8 
Platelet Factor (PF)-4 
"y-Interferon Inducible Protein 10 (IP-10) 
Monocyte Chemotactic Peptide (MCP)-I  (=MCAF) 
MIP-Related Protein (MRP)-I 
MRP-2 
ENA-78 
Steel Factor 
Flt3-1igand 
Information on these molecules can be found in references 1-7, 24-30. poietic cells. Will IL-17 be found to be merely a redundant 
cytokine  floating,  after induction  of its  production,  in  a 
"sea" of other redundant  cytokines? The full range of cy- 
tokine-induction  capacities of individual  cytokines is  not 
known  and perhaps someday some ambitious investigator 
will have the energy to do a comparative analysis of which 
cytokines induce the production/release of what cytokines 
from which cells.  Some of this can already be gleaned from 
the literature, but it would be best for variables to be con- 
trolled within  a  laboratory using  the  same  cytokines and 
cell preparations. This would give us some insight into the 
overlapping  and  non-overlapping  inductive  capacities  of 
individual cytokines. Redundancy in action itself does not 
mean  the  biomolecule  is  not  important.  Redundancy  is 
probably  the  means  by  which  the  body  protects  itself 
against insults that may disturb the production or action of 
one or more cytokines or cytokine receptors. Many cyto- 
kines can be currently classified  in this redundant, but nec- 
essary category for "safety fall backs." 
Sometimes, what a cytokine cannot do is as informative 
to its overall place in an interacting network as to what the 
cytokine can do.  Steel factor (SLF)  and Flt3-1igand (L) are 
both produced by stromal cells (30, 41) and are ligands for 
tyrosine kinase receptors.  SLF and FIt3-L are very potent 
co-stimulating cytokines for early hematopoietic cells  (29, 
30). Whether or not SLF and Flt3-L ~ll into the category 
of IL-17-inducible proteins would be valuable information. 
Since  cytokines can  act synergistically to  induce  produc- 
tion/release ofcytokines (17-20, 31), the effects of multiple 
cytokines would also have to be taken into  consideration. 
This makes comparative categorizing of the  cytokine in- 
ductive  capacities  of different  cytokines  an  even  more 
daunting task.  Out of necessity, these studies Hill have to 
be done in vitro using highly purified cell populations and 
their subsets. In the paper by Fossiez et al. (31), TNF-ot and 
IFN-y were found to have additive effects on the IL-17- 
induced secretion oflL-6; while neither IL-17 nor TNF-o~ 
induced  release  of GM-CSF,  the  combination  of IL-17 
plus TNF-c~ was effective in this event. Induction of pro- 
duction  of cytokines by IL-17, alone and in combination 
with other cytokines, can be through transcriptional, post- 
transcriptional  or  the  combination  of transcriptional  and 
posttranscriptional effects, and it is highly possible that the 
mechanisms of cytokine production will not be similar in all 
cases. The observation by Yao et al.  (34) that murine IL-17 
stimulates activity of the transcriptional factor NF-K B, which 
is known to regulate a number of gene products involved 
in  cell activation and  growth  control  (reviewed in  refer- 
ence 34), offers the possibility that some of the cytokine in- 
duction effects oflL-17 may be mediated by a common in- 
tracellular event.  It has been noted that both glycosylated 
and non-glycosylated forms of the homodimeric IL-17 mol- 
ecule are secreted (31, 33). It would be of interest to know 
if the activities of IL-17 relate to the glycosylated state. 
How these in vitro activities relate to the in vivo situa- 
tion is more difficult to evaluate. One method to evaluate 
this is to administer IL-17 to mice. R.esults  of such studies 
could set the stage for clinical evaluation of this molecule. 
Also, whether a portion of the  IL-17 molecule or a small 
peptide with sequence homology to IL-17 ~  be shown 
to have similar activities may be of interest.  Peptides  that 
induce  the  release  of cytokines  are  available  (42,  43).  A 
molecule or peptide that induces the release of a number of 
other cytokines may be of value clinically,  as long as  the 
combined  effects of the  induced  molecules  don't  cancel 
each other out (43). 
Is the function of IL-17 only to induce the production of 
other  cytokines?  Efforts  in  this  area  may  be  clarified 
through the use of mice in which the genes for IL-17 and/ 
or the  IL-17 receptor are  "knocked-out." Whether these 
"knock-outs" will be embryonic lethal,  or result in func- 
tional abnormalities could shed light on whether IL-17 is 
merely another  molecule  with  redundant  activities,  or  if 
functions of IL-17 not yet recognized are in the offering. 
The ubiquitous expression of the IL-17 receptor gene (34) 
suggest the possibility of other functions for IL-17. More- 
over, abnormalities could suggest a role for IL-17 in human 
disease progression. 
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